Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008. The intensive protocol, dividing patients into 4 risk groups depending mainly on response to treatment, is now used for ALL patients 1-45 years in Denmark, Norway, Sweden, Finland, Iceland, Lithuania and Estonia. The joint effort of pediatricians and adult hematologists has resulted in new knowledge especially for teenagers and adult patients and has revealed that: 1. adult patients are more often ‘high risk’ patients compared with children, 2. they tolerate intensive chemotherapy almost as well as children and are not subject to delays or gaps during treatment, and 3. when comparing patients within the 4 risk groups, adult survival is close to that of children and is markedly improved.

Presenter: Dr Nina Toft

Affiliation: Herlev University Hospital, Herlev, Denmark

Topic: ADULTS AND CHILDREN (1-45 YEARS) WITH PH-NEGATIVE ALL HAVE ALMOST IDENTICAL OUTCOME IN RISK-STRATIFIED ANALYSIS OF NOPHO ALL2008

Abstract LB173 will be presented by Nina Toft on Friday, June 10, 2016, 17:15 - 17:30 in Hall H.

 

About the EHA Annual Congress

Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments. The latest data on research and developments will be presented. The topics range from stem cell physiology and development, to leukemia, lymphoma, myeloma - diagnosis and treatment; red blood cells -, white blood cells- and platelet disorders; thrombosis and bleeding disorders.

Contact

EHA Executive Office

Ineke van der Beek, Jon Tarifa

E-mail: communication@ehaweb.org

Mobile: +31(0)6 2011 1055

 

 

Last Updated on Tuesday 05 June 2018.